Evidence map›Paper›PMID 28064632›Full record

ArticlePharmaceutical biology2017

Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice.

Samar M Hassan, Marwa M Khalaf, Sawsan A Sadek, Amira M Abo-Youssef

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Antiapoptotic and antinociceptive effects ofResearch in pharmaceutical sciences · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. The Nephroprotective Activity ofJournal of experimental pharmacology · 2024
    Article
  14. Review
  15. Review
  16. The ameliorative effect ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samar M Hassana Department of Pharmacology and Toxicology, Faculty of Pharmacy , Fayoum University , Fayoum , Egypt.
Marwa M Khalafb Department of Pharmacology and Toxicology, Faculty of Pharmacy , Beni-Suef University , Beni-Suef , Egypt.
Sawsan A Sadekc Department of Pharmacology and Toxicology, Faculty of Medicine , Fayoum University , Fayoum, Egypt.
Amira M Abo-Youssefb Department of Pharmacology and Toxicology, Faculty of Pharmacy , Beni-Suef University , Beni-Suef , Egypt.
Beni-Suef University · EGFayoum University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextCurrently, the outcomes of the use of cisplatin in cancer therapy is limited by nephrotoxicity.

objectiveThis study aims to investigate the nephroprotective role of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice. MATERIALS AND

methodsAdult female Wistar Albino mice were divided into eight groups (n = 8). Group I served as normal control. Groups II, III and IV received apigenin (3 mg/kg, i.p.), myricetin (3 mg/kg, i.p.) or their combination respectively, for seven days. Group V served as positive control group, received vehicles for seven days and cisplatin (7.5 mg/kg, i.p.) for three days starting at day five. Groups VI, VII and VIII received apigenin, myricetin or their combination, respectively for seven days as well as cisplatin injection for three days starting at day five. by the end of the experimental period, a biochemical study involving, nephrotoxicity markers [serum creatinine (Cr) and blood urea nitrogen (BUN)], apoptotic marker [caspase 3], inflammatory mediators [tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), cyclooxygenase I and II (COXI, COXII)] and oxidative stress biomarkers [malondialdehyde (MDA), reduced glutathione (GSH) and catalase] was conducted. In addition, renal histopathological alterations were evaluated.

resultsApigenin, myricetin and their combination significantly reduced blood BUN, serum Cr, caspase-3TNF-α, IL-6, COXI and COXII, MDA levels and significantly increased GSH level and catalase activity parallel to, histopathological improvement in kidney tissues. DISCUSSION AND

conclusionApigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.

Indexed as

AnimalsAntineoplastic AgentsApigeninCaspase 3CisplatinFemaleFlavonoidsKidneyMiceOxidative StressTumor Necrosis Factor-alphaAntineoplastic AgentsApigeninCaspase 3CisplatinFlavonoidsmyricetinTumor Necrosis Factor-alphaanti-inflammatoryAntineoplasticantioxidantinflammationoxidative stressprophylaxis

Identifiers

PMID28064632
PMCPMC6130592
OpenAlexW2570620560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.